RU2008122779A - Соединения для ингибирования фермента - Google Patents
Соединения для ингибирования фермента Download PDFInfo
- Publication number
- RU2008122779A RU2008122779A RU2008122779/04A RU2008122779A RU2008122779A RU 2008122779 A RU2008122779 A RU 2008122779A RU 2008122779/04 A RU2008122779/04 A RU 2008122779/04A RU 2008122779 A RU2008122779 A RU 2008122779A RU 2008122779 A RU2008122779 A RU 2008122779A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- compound according
- alkyl
- independently
- substituent
- Prior art date
Links
- 0 CC(C)CC(C(C1(C)OC1)=O)NC([C@](COC)NC(C(COC)NC(c1n[o]*(C)c1)=O)=O)=O Chemical compound CC(C)CC(C(C1(C)OC1)=O)NC([C@](COC)NC(C(COC)NC(c1n[o]*(C)c1)=O)=O)=O 0.000 description 2
- LGAOYYYWTTXCEX-OJVMJSSBSA-N CC(C)CC(C(C1(C)OC1)=O)NC([C@H](C)NC(C(COC)NC(c1n[o]c(C)c1)=O)=O)=O Chemical compound CC(C)CC(C(C1(C)OC1)=O)NC([C@H](C)NC(C(COC)NC(c1n[o]c(C)c1)=O)=O)=O LGAOYYYWTTXCEX-OJVMJSSBSA-N 0.000 description 1
- OMFJGXMPSYXWCE-BFGVMEHQSA-N CC(C)CC(C(C1(C)OC1)=O)NC([C@H](Cc1c[s]cn1)NC(C(COC)NC(c1n[o]c(C)c1)=O)=O)=O Chemical compound CC(C)CC(C(C1(C)OC1)=O)NC([C@H](Cc1c[s]cn1)NC(C(COC)NC(c1n[o]c(C)c1)=O)=O)=O OMFJGXMPSYXWCE-BFGVMEHQSA-N 0.000 description 1
- WHBBNXVJTBOKBT-DREYXHSYSA-N CC(C)CC(C([C@]1(C)OC1)=O)NC(C(Cc1ccccc1)NC(C(COC)NC(c1ccn[o]1)=O)=O)=O Chemical compound CC(C)CC(C([C@]1(C)OC1)=O)NC(C(Cc1ccccc1)NC(C(COC)NC(c1ccn[o]1)=O)=O)=O WHBBNXVJTBOKBT-DREYXHSYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Соединение, имеющее структуру формулы (I) или его фармацевтически приемлемая соль ! ! в которой L выбран из С=О, C=S и SO2; ! Х выбран из О, S, NH и N-C1-6-алкила; ! Z отсутствует или представляет собой С1-6-алкил или С1-6-алкоксигруппу; ! каждый из R1, R2 и R3 независимо друг от друга выбран из водорода, С1-6-алкила, ! С1-6-алкенила, С1-6-алкинила, С1-6-гидроксиалкила, С1-6-алкоксиалкила, арила, С1-6-аралкила, гетероарила, гетероциклила, С1-6-гетероциклоалкила, С1-6-гетероаралкила, карбоциклила и С1-6-карбоциклоалкила; ! R4 выбран из водорода, С1-6-аралкила и С1-6-алкила; ! R5 представляет собой гетероарил и ! R6 и R7 независимо друг от друга выбраны из водорода, С1-6-алкила и С1-6-аралкила. ! 2. Соединение по п.1, в котором Z отсутствует. ! 3. Соединение по п.1, в котором R4, R6 и R7 независимо друг от друга выбраны из водорода и метила. ! 4. Соединение по п.1, в котором L представляет собой С=О. ! 5. Соединение по п.1, в котором L представляет собой SO2. ! 6. Соединение по п.1, в котором R1, R2 и R3 независимо друг от друга выбраны из водорода, С1-6-алкила, С1-6-алкенила, С1-6-алкинила, С1-6-гидроксиалкила, С1-6-алкоксиалкила, С1-6-аралкила, С1-6-гетероциклоалкила, С1-6-гетероаралкила и С1-6-карбоциклоалкила. ! 7. Соединение по п.6, в котором любой из R1, R2 и R3 независимо друг от друга представляет собой С1-6-алкил. ! 8. Соединение по п.7, в котором любой из R1, R2 и R3 независимо друг от друга выбран из метила, этила, пропила, изопропила, бутила, втор-бутила и изобутила. ! 9. Соединение по п.6, в котором любой из R1, R2 и R3 независимо друг от друга представляет собой пропаргил. ! 10. Соединение по п.6, в котором любой из R1, R2 и R3 независимо друг от друга представляет собой С1-6-гидроксиалкил. ! 11. Соединение по п.10, в котором любой из R1, R2 и R3 неза�
Claims (52)
1. Соединение, имеющее структуру формулы (I) или его фармацевтически приемлемая соль
в которой L выбран из С=О, C=S и SO2;
Х выбран из О, S, NH и N-C1-6-алкила;
Z отсутствует или представляет собой С1-6-алкил или С1-6-алкоксигруппу;
каждый из R1, R2 и R3 независимо друг от друга выбран из водорода, С1-6-алкила,
С1-6-алкенила, С1-6-алкинила, С1-6-гидроксиалкила, С1-6-алкоксиалкила, арила, С1-6-аралкила, гетероарила, гетероциклила, С1-6-гетероциклоалкила, С1-6-гетероаралкила, карбоциклила и С1-6-карбоциклоалкила;
R4 выбран из водорода, С1-6-аралкила и С1-6-алкила;
R5 представляет собой гетероарил и
R6 и R7 независимо друг от друга выбраны из водорода, С1-6-алкила и С1-6-аралкила.
2. Соединение по п.1, в котором Z отсутствует.
3. Соединение по п.1, в котором R4, R6 и R7 независимо друг от друга выбраны из водорода и метила.
4. Соединение по п.1, в котором L представляет собой С=О.
5. Соединение по п.1, в котором L представляет собой SO2.
6. Соединение по п.1, в котором R1, R2 и R3 независимо друг от друга выбраны из водорода, С1-6-алкила, С1-6-алкенила, С1-6-алкинила, С1-6-гидроксиалкила, С1-6-алкоксиалкила, С1-6-аралкила, С1-6-гетероциклоалкила, С1-6-гетероаралкила и С1-6-карбоциклоалкила.
7. Соединение по п.6, в котором любой из R1, R2 и R3 независимо друг от друга представляет собой С1-6-алкил.
8. Соединение по п.7, в котором любой из R1, R2 и R3 независимо друг от друга выбран из метила, этила, пропила, изопропила, бутила, втор-бутила и изобутила.
9. Соединение по п.6, в котором любой из R1, R2 и R3 независимо друг от друга представляет собой пропаргил.
10. Соединение по п.6, в котором любой из R1, R2 и R3 независимо друг от друга представляет собой С1-6-гидроксиалкил.
11. Соединение по п.10, в котором любой из R1, R2 и R3 независимо друг от друга выбран из гидроксиметила и гидроксиэтила.
12. Соединение по п.6, в котором любой из R1, R2 и R3 независимо друг от друга представляет собой С1-6-алкоксиалкил.
13. Соединение по п.12, в котором любой из R1, R2 и R3 независимо друг от друга выбран из метоксиметила и метоксиэтила.
14. Соединение по п.6, в котором любой из R1, R2 и R3 независимо друг от друга представляет собой С1-6-гетероаралкил.
15. Соединение по п.14, в котором любой из R1, R2 и R3 независимо друг от друга выбран из имидазолилметила, пиразолилметила и тиазолилметила и пиридилметила.
16. Соединение по п.6, в котором любой из R1, R2 и R3 независимо друг от друга представляет собой циклогексилметил.
17. Соединение по п.1, в котором все R1, R2 и R3 различны.
18. Соединение по п.1, в котором по меньшей мере один из R1 и R2 выбран из С1-6-гидроксиалкила и С1-6-алкоксиалкила.
19. Соединение по п.18, в котором по меньшей мере один из R1 и R2 представляет собой С1-6-алкоксиалкил.
20. Соединение по п.19, в котором по меньшей мере один из R1 и R2 выбран из метоксиметила и метоксиэтила.
21. Соединение по п.1 или 18, в котором R3 выбран из С1-6-алкила и С1-6-аралкила.
22. Соединение по п.21, в котором R3 представляет собой С1-6алкил.
23. Соединение по п.22, в котором R3 выбран из метила, этила, изопропила, втор-бутила и изобутила.
24. Соединение по п.23, в котором R3 представляет собой изобутил.
25. Соединение по п.21, в котором R3 представляет собой С1-6-аралкил.
26. Соединение по п.25, в котором R3 представляет собой фенилметил.
27. Соединение по п.1, в котором R5 представляет собой 5- или 6-членный гетероарил.
28. Соединение по п.27, в котором R5 выбран из изоксазола, изотиазола, фурана, тиофена, оксазола, тиазола, пиразола или имидазола.
29. Соединение по п.28, в котором R5 выбран из изоксазола, фурана или тиофена.
30. Соединение по п.29, в котором R5 представляет собой фуран или тиофен.
31. Соединение по п.30, в котором R5 представляет собой незамещенный фуран-3-ил или тиен-2-ил.
32. Соединение по п.29, в котором R5 представляет собой изоксазол-3-ил или изоксазол-5-ил.
33. Соединение по п.32, в котором R5 представляет собой изоксазол-3-ил, содержащий заместитель в 5-положении.
34. Соединение по п.32, в котором R5 представляет собой изоксазол-5-ил, содержащий заместитель в 3-положении.
35. Соединение по п.33 или 34, в котором заместитель выбран из С1-6-алкила, С1-6-алкоксигруппы, С1-6-алкоксиалкила, С1-6-гидроксиалкила, остатка карбоновой кислоты, аминокарбоксилата, С1-6-алкиламинокарбоксилата, (С1-6-алкил)2аминокарбоксилата, С1-6-алкилкарбоксилата, С1-6-гетероаралкила, С1-6-аралкила, С1-6-гетероциклоалкила и С1-6-карбоциклоалкила.
36. Соединение по п.35, в котором заместитель выбран из метила, этила, изопропила и циклопропилметила.
37. Соединение по п.35, в котором заместитель выбран из С1-6-гетероаралкила и
С1-6-гетероциклоалкила.
38. Соединение по п.37, в котором заместитель представляет собой 1,2,4-триазол-5-илметил.
39. Соединение по п.37, в котором заместитель представляет собой азетидин-1-илметил.
41. Соединение по п.40, в котором W представляет собой О.
42. Соединение по п.37, в котором заместитель выбран из С1-6-алкоксигруппы и С1-6-алкоксиалкила.
43. Соединение по п.42, в котором заместитель выбран из метоксигруппы, этоксигруппы, метоксиметила и метоксиэтила.
44. Соединение по п.37, в котором заместитель выбран из карбоновой кислоты, аминокарбоксилата, С1-6-алкиламинокарбоксилата, (С1-6-алкил)2-аминокарбоксилата или С1-6-алкилкарбоксилата.
45. Соединение по п.44, в котором заместитель представляет собой метилкарбоксилат.
47. Фармацевтическая композиция, содержащая соединение по любому из пп.1-46 и фармацевтически приемлемый разбавитель или носитель.
48. Фармацевтическая композиция по п.47, которая биодоступна перорально.
49. Способ лечения воспаления, нейродегенеративного заболевания, мышечной дистрофии, рака, хронических инфекционных заболеваний, гиперпролиферативного состояния, атрофии мышц и иммунно-зависимых состояний, предусматривающий введение терапевтически эффективного количества фармацевтической композиции по п.48.
50. Способ ингибирования или уменьшения ВИЧ-инфекции, предусматривающий введение терапевтически эффективного количества фармацевтической композиции по п.48.
51. Способ воздействия на уровень экспрессии генов вируса у субъекта, предусматривающий введение терапевтически эффективного количества фармацевтической композиции по п.48.
52. Способ изменения варьирования антигенных пептидов, продуцированных протеасомой в организме, предусматривающий введение терапевтически эффективного количества фармацевтической композиции по п.48.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73611805P | 2005-11-09 | 2005-11-09 | |
US60/736,118 | 2005-11-09 | ||
US84258206P | 2006-09-05 | 2006-09-05 | |
US60/842,582 | 2006-09-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012110718/04A Division RU2012110718A (ru) | 2005-11-09 | 2012-03-20 | Соединения для ингибирования фермента |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2008122779A true RU2008122779A (ru) | 2009-12-20 |
RU2453556C2 RU2453556C2 (ru) | 2012-06-20 |
Family
ID=37671954
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008122779/04A RU2453556C2 (ru) | 2005-11-09 | 2006-11-09 | Соединения для ингибирования фермента |
RU2012110718/04A RU2012110718A (ru) | 2005-11-09 | 2012-03-20 | Соединения для ингибирования фермента |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012110718/04A RU2012110718A (ru) | 2005-11-09 | 2012-03-20 | Соединения для ингибирования фермента |
Country Status (29)
Country | Link |
---|---|
US (8) | US7687456B2 (ru) |
EP (2) | EP2623113B1 (ru) |
JP (3) | JP5436860B2 (ru) |
KR (3) | KR101274417B1 (ru) |
CN (2) | CN105237621A (ru) |
AU (1) | AU2006311584B2 (ru) |
BR (1) | BRPI0618468A2 (ru) |
CA (1) | CA2629084C (ru) |
CY (1) | CY1119405T1 (ru) |
DK (2) | DK2623113T3 (ru) |
EC (1) | ECSP088460A (ru) |
ES (2) | ES2628620T3 (ru) |
GT (1) | GT200800063A (ru) |
HK (2) | HK1121172A1 (ru) |
HN (1) | HN2008000738A (ru) |
HU (1) | HUE034863T2 (ru) |
IL (2) | IL191344A (ru) |
LT (1) | LT2623113T (ru) |
MX (1) | MX2008006090A (ru) |
MY (2) | MY171061A (ru) |
NZ (2) | NZ595196A (ru) |
PH (1) | PH12013501656A1 (ru) |
PL (2) | PL1948678T3 (ru) |
PT (2) | PT1948678E (ru) |
RU (2) | RU2453556C2 (ru) |
SI (1) | SI2623113T1 (ru) |
SV (1) | SV2009002903A (ru) |
WO (1) | WO2007056464A1 (ru) |
ZA (1) | ZA200804455B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2450016C2 (ru) * | 2006-06-19 | 2012-05-10 | Протеоликс, Инк. | Пептидные эпоксикетоны для ингибирования протеасомы |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1745064E (pt) | 2004-04-15 | 2011-03-23 | Proteolix Inc | Compostos para a inibição de uma enzima de proteassoma |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
JP5108509B2 (ja) * | 2004-05-10 | 2012-12-26 | プロテオリックス, インコーポレイテッド | 酵素阻害のための化合物 |
DK2623113T3 (en) | 2005-11-09 | 2017-07-17 | Onyx Therapeutics Inc | Enzyme inhibition compound |
WO2008140782A2 (en) * | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
DK2207791T4 (da) * | 2007-10-04 | 2019-10-07 | Onyx Therapeutics Inc | Krystallinske peptidepoxyketon-proteasehæmmere og syntese af aminosyreketoepoxider |
JP5554720B2 (ja) * | 2007-12-19 | 2014-07-23 | エイボン プロダクツ インコーポレーテッド | 非タンパク質性アミノ酸を含む局所用組成物 |
ES2617560T3 (es) | 2008-10-21 | 2017-06-19 | Onyx Therapeutics, Inc. | Combinación del inhibidor del proteasoma de epoxicetona peptídica carfilzomib con melfalán para su uso en el tratamiento del mieloma múltiple |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
EP2498793B1 (en) * | 2009-11-13 | 2019-07-10 | Onyx Therapeutics, Inc. | Oprozomib for use in metastasis suppression |
MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
WO2011136905A2 (en) | 2010-04-07 | 2011-11-03 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
WO2013112601A1 (en) | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
US20130303482A1 (en) * | 2012-05-08 | 2013-11-14 | Onyx Therapeutics, Inc. | Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors |
EP2869820A4 (en) | 2012-07-09 | 2016-02-17 | Onyx Therapeutics Inc | PRODRUGS OF PEPTIDEPOXIDE KETONE PROTEASE INHIBITORS |
AU2013302269A1 (en) * | 2012-08-14 | 2015-03-12 | Trillium Therapeutics Inc. | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors |
TW201422255A (zh) * | 2012-10-24 | 2014-06-16 | Onyx Therapeutics Inc | 用於蛋白酶體抑制劑之調整釋放製劑 |
AR095426A1 (es) * | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
EA030957B1 (ru) * | 2013-03-14 | 2018-10-31 | Оникс Терапьютикс, Инк. | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы |
AU2014290012B2 (en) | 2013-07-19 | 2020-01-16 | Onyx Therapeutics, Inc. | Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers |
CN104945470B (zh) * | 2014-03-30 | 2020-08-11 | 浙江大学 | 杂环构建的三肽环氧酮类化合物及制备和应用 |
TR201816372T4 (tr) | 2014-07-14 | 2018-11-21 | Centrax Int Inc | Enzim inhibisyonu için etoksiketon bileşikleri. |
EP4180041A1 (en) | 2014-08-07 | 2023-05-17 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
US20160115198A1 (en) | 2014-10-27 | 2016-04-28 | Apicore Us Llc | Methods of making carfilzomib and intermediates thereof |
US9980976B2 (en) * | 2015-02-17 | 2018-05-29 | Northwestern University | Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists |
US11306107B2 (en) | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
AR108919A1 (es) | 2016-06-29 | 2018-10-10 | Kezar Life Sciences | Proceso de preparación del inhibidor de inmunoproteasoma de péptido epoxicetona, y sus precursores |
MX2018016387A (es) | 2016-06-29 | 2019-09-09 | Kezar Life Sciences | Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona. |
KR101720736B1 (ko) | 2016-12-15 | 2017-03-28 | 이숙자 | 스플린트용 커버 조립체 |
EP3589659A4 (en) | 2017-02-28 | 2021-03-24 | Mayo Foundation for Medical Education and Research | CANCER TREATMENT COMPOUNDS AND METHODS |
BR112020005079A2 (pt) | 2017-09-14 | 2020-09-15 | Glaxosmithkline Intellectual Property Development Limited | tratamento de combinação para câncer |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
CN110092813B (zh) * | 2019-06-05 | 2021-05-11 | 南京师范大学 | 一种三肽环氧丙烷衍生物及其制备方法和用途 |
KR20220162155A (ko) * | 2020-04-27 | 2022-12-07 | 주식회사 오토텍바이오 | Ubr 박스 도메인 리간드로의 화합물 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5135919A (en) * | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
US5441944A (en) * | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
US5071957A (en) | 1989-08-04 | 1991-12-10 | Bristol-Myers Company | Antibiotic BU-4061T |
US4990448A (en) | 1989-08-04 | 1991-02-05 | Bristol-Myers Company | Bu-4061T |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
CA2077665A1 (en) | 1990-03-05 | 1991-09-06 | Robert Siman | Chymotrypsin-like proteases and their inhibitors |
US5340736A (en) * | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
US5519029A (en) * | 1992-09-08 | 1996-05-21 | Boehringer Mannheim Italia, S.P.A. | 2-aminoalkyl-5-aminoalkylamino substituted-isoquinoindazole-6(2H)-ones |
GB9300048D0 (en) * | 1993-01-04 | 1993-03-03 | Wellcome Found | Endothelin converting enzyme inhibitors |
TW380137B (en) | 1994-03-04 | 2000-01-21 | Merck & Co Inc | Process for making an epoxide |
US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6660268B1 (en) * | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
US6506876B1 (en) * | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
DE19505263A1 (de) | 1995-02-16 | 1996-08-22 | Consortium Elektrochem Ind | Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
SI0932617T1 (en) | 1996-10-18 | 2002-06-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
IL129407A0 (en) * | 1996-10-18 | 2000-02-17 | Vertex Pharma | Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof |
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
AU750207B2 (en) * | 1997-06-13 | 2002-07-11 | Cydex Pharmaceuticals, Inc. | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
US6133308A (en) * | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
US6075150A (en) * | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
US6099851A (en) * | 1998-06-02 | 2000-08-08 | Weisman; Kenneth M. | Therapeutic uses of leuprolide acetate |
US6902721B1 (en) * | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6838436B1 (en) * | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6462019B1 (en) * | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
CA2347275C (en) * | 1998-10-20 | 2010-03-09 | Millennium Pharmaceuticals, Inc. | Method for monitoring proteasome inhibitor drug action |
US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
EP1741428A3 (en) * | 1999-08-13 | 2007-05-09 | Biogen Idec MA, Inc. | Cell adhesion inhibitors |
CA2385958A1 (en) | 1999-10-20 | 2001-04-26 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone and hair growth |
KR20030038727A (ko) * | 2000-09-04 | 2003-05-16 | 소니 가부시끼 가이샤 | 반사층, 반사층을 구비한 광학 기록 매체 및 반사층형성용 스퍼터링 타겟 |
PT1326632E (pt) | 2000-10-12 | 2007-01-31 | Viromics Gmbh | Tratamento para o tratamento de infecções por vírus da hepatite |
US6713446B2 (en) * | 2001-01-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Formulation of boronic acid compounds |
EP1392355B1 (en) * | 2001-05-21 | 2007-02-14 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
US7524883B2 (en) * | 2002-01-08 | 2009-04-28 | Eisai R&D Management Co., Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
US20040116329A1 (en) * | 2002-01-29 | 2004-06-17 | Epstein Stephen E. | Inhibition of proteasomes to prevent restenosis |
WO2003086283A2 (en) | 2002-04-09 | 2003-10-23 | Greenville Hospital System | Metastasis modulating activity of highly sulfated oligosaccharides |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20030224469A1 (en) | 2002-06-03 | 2003-12-04 | Buchholz Tonia J. | Methods and kits for assays utilizing fluorescence polarization |
AU2003249682A1 (en) * | 2002-06-03 | 2003-12-19 | Als Therapy Development Foundation | Treatment of neurodegenerative diseases using proteasome modulators |
AU2003256847A1 (en) * | 2002-07-26 | 2004-02-16 | Advanced Research And Technology Institute At Indiana University | Method of treating cancer |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
TW200418791A (en) * | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
EP2316431B1 (en) | 2003-04-08 | 2015-09-30 | Novartis AG | Solid oral composition comprising a S1P receptor agonist and a sugar alcohol |
ATE506456T1 (de) * | 2003-06-10 | 2011-05-15 | David Gladstone Inst | Verfahren zur behandlung von lentivirusinfektionen |
US7012063B2 (en) | 2003-06-13 | 2006-03-14 | Children's Medical Center Corporation | Reducing axon degeneration with proteasome inhibitors |
BRPI0418386A (pt) | 2003-12-31 | 2007-05-22 | Cydex Inc | formulação inalante contendo éter sulfoalquìlico gama-ciclodextrina e corticosteróide |
GB0400804D0 (en) * | 2004-01-14 | 2004-02-18 | Innoscience Technology Bv | Pharmaceutical compositions |
US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
PT1745064E (pt) * | 2004-04-15 | 2011-03-23 | Proteolix Inc | Compostos para a inibição de uma enzima de proteassoma |
JP5108509B2 (ja) * | 2004-05-10 | 2012-12-26 | プロテオリックス, インコーポレイテッド | 酵素阻害のための化合物 |
US20050256324A1 (en) | 2004-05-10 | 2005-11-17 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
EP1805208A2 (en) * | 2004-10-20 | 2007-07-11 | Proteolix, Inc. | Labeled compounds for proteasome inhibition |
HUE027850T2 (en) * | 2004-12-07 | 2016-11-28 | Onyx Therapeutics Inc | Preparation for proteasome inhibition |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7589066B2 (en) * | 2005-03-11 | 2009-09-15 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
WO2006113470A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
DK2623113T3 (en) * | 2005-11-09 | 2017-07-17 | Onyx Therapeutics Inc | Enzyme inhibition compound |
AR057227A1 (es) | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
US20070207950A1 (en) * | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
WO2007122686A1 (ja) * | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
DE102006026464A1 (de) * | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
US7691852B2 (en) * | 2006-06-19 | 2010-04-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
WO2008033807A2 (en) | 2006-09-13 | 2008-03-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic proteasome inhibitors for the treatment of cancer |
WO2008091620A2 (en) | 2007-01-23 | 2008-07-31 | Gloucester Pharmaceuticals, Inc. | Combination therapy comprising romidepsin and i.a. bortezomib |
JP4325683B2 (ja) * | 2007-02-14 | 2009-09-02 | セイコーエプソン株式会社 | 画像表示装置、及び画像表示装置の制御方法 |
WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
SI2178888T1 (sl) | 2007-08-06 | 2012-11-30 | Millennium Pharm Inc | Proteasomni inhibitorji |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
DK2207791T4 (da) * | 2007-10-04 | 2019-10-07 | Onyx Therapeutics Inc | Krystallinske peptidepoxyketon-proteasehæmmere og syntese af aminosyreketoepoxider |
WO2009051581A1 (en) | 2007-10-16 | 2009-04-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
US7838673B2 (en) * | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
WO2009067453A1 (en) | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
SG194349A1 (en) | 2008-06-17 | 2013-11-29 | Millennium Pharm Inc | Boronate ester compounds and pharmaceutical compositions thereof |
AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
ES2617560T3 (es) * | 2008-10-21 | 2017-06-19 | Onyx Therapeutics, Inc. | Combinación del inhibidor del proteasoma de epoxicetona peptídica carfilzomib con melfalán para su uso en el tratamiento del mieloma múltiple |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
CN101928329B (zh) | 2009-06-19 | 2013-07-17 | 北京大学 | 三肽硼酸(酯)类化合物、其制备方法和应用 |
EP2498793B1 (en) | 2009-11-13 | 2019-07-10 | Onyx Therapeutics, Inc. | Oprozomib for use in metastasis suppression |
MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
NZ602622A (en) | 2010-03-31 | 2015-01-30 | Millennium Pharm Inc | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
WO2011136905A2 (en) | 2010-04-07 | 2011-11-03 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
-
2006
- 2006-11-09 DK DK13157801.5T patent/DK2623113T3/en active
- 2006-11-09 DK DK06837164.0T patent/DK1948678T3/da active
- 2006-11-09 BR BRPI0618468-5A patent/BRPI0618468A2/pt active Search and Examination
- 2006-11-09 EP EP13157801.5A patent/EP2623113B1/en not_active Not-in-force
- 2006-11-09 US US11/595,804 patent/US7687456B2/en not_active Expired - Fee Related
- 2006-11-09 NZ NZ595196A patent/NZ595196A/xx not_active IP Right Cessation
- 2006-11-09 PT PT68371640T patent/PT1948678E/pt unknown
- 2006-11-09 PT PT131578015T patent/PT2623113T/pt unknown
- 2006-11-09 PL PL06837164T patent/PL1948678T3/pl unknown
- 2006-11-09 CA CA2629084A patent/CA2629084C/en not_active Expired - Fee Related
- 2006-11-09 US US12/084,838 patent/US8716322B2/en not_active Expired - Fee Related
- 2006-11-09 RU RU2008122779/04A patent/RU2453556C2/ru not_active IP Right Cessation
- 2006-11-09 ES ES13157801.5T patent/ES2628620T3/es active Active
- 2006-11-09 MX MX2008006090A patent/MX2008006090A/es active IP Right Grant
- 2006-11-09 SI SI200632181T patent/SI2623113T1/sl unknown
- 2006-11-09 CN CN201510695570.1A patent/CN105237621A/zh active Pending
- 2006-11-09 CN CN200680050739.7A patent/CN101405294B/zh not_active Expired - Fee Related
- 2006-11-09 JP JP2008540164A patent/JP5436860B2/ja not_active Expired - Fee Related
- 2006-11-09 NZ NZ568068A patent/NZ568068A/en not_active IP Right Cessation
- 2006-11-09 HU HUE13157801A patent/HUE034863T2/en unknown
- 2006-11-09 LT LTEP13157801.5T patent/LT2623113T/lt unknown
- 2006-11-09 PL PL13157801T patent/PL2623113T3/pl unknown
- 2006-11-09 WO PCT/US2006/043503 patent/WO2007056464A1/en active Application Filing
- 2006-11-09 KR KR1020127026322A patent/KR101274417B1/ko active IP Right Grant
- 2006-11-09 ES ES06837164T patent/ES2415756T3/es active Active
- 2006-11-09 MY MYPI2011005413A patent/MY171061A/en unknown
- 2006-11-09 MY MYPI20081524A patent/MY145757A/en unknown
- 2006-11-09 KR KR1020137007728A patent/KR101434522B1/ko active IP Right Grant
- 2006-11-09 EP EP06837164.0A patent/EP1948678B1/en not_active Not-in-force
- 2006-11-09 AU AU2006311584A patent/AU2006311584B2/en not_active Ceased
-
2008
- 2008-05-09 GT GT200800063A patent/GT200800063A/es unknown
- 2008-05-09 SV SV2008002903A patent/SV2009002903A/es active IP Right Grant
- 2008-05-09 HN HN2008000738A patent/HN2008000738A/es unknown
- 2008-05-11 IL IL191344A patent/IL191344A/en not_active IP Right Cessation
- 2008-05-19 EC EC2008008460A patent/ECSP088460A/es unknown
- 2008-05-22 ZA ZA200804455A patent/ZA200804455B/xx unknown
- 2008-05-29 KR KR1020087012924A patent/KR101275445B1/ko active IP Right Grant
-
2009
- 2009-01-29 HK HK09100839.6A patent/HK1121172A1/xx not_active IP Right Cessation
-
2012
- 2012-03-20 RU RU2012110718/04A patent/RU2012110718A/ru not_active Application Discontinuation
- 2012-08-13 JP JP2012179414A patent/JP5778097B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-08 US US13/736,605 patent/US20130130968A1/en not_active Abandoned
- 2013-08-07 JP JP2013164037A patent/JP5799060B2/ja not_active Expired - Fee Related
- 2013-08-08 PH PH12013501656A patent/PH12013501656A1/en unknown
- 2013-09-26 US US14/038,515 patent/US9205124B2/en not_active Expired - Fee Related
- 2013-09-26 US US14/038,626 patent/US9205126B2/en not_active Expired - Fee Related
- 2013-09-26 US US14/038,591 patent/US9205125B2/en not_active Expired - Fee Related
-
2015
- 2015-10-26 IL IL242282A patent/IL242282B/en not_active IP Right Cessation
- 2015-12-07 US US14/960,957 patent/US20160083421A1/en not_active Abandoned
-
2016
- 2016-07-13 HK HK16108193.0A patent/HK1220208A1/zh unknown
-
2017
- 2017-05-26 US US15/606,076 patent/US10150794B2/en not_active Expired - Fee Related
- 2017-07-21 CY CY20171100781T patent/CY1119405T1/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2450016C2 (ru) * | 2006-06-19 | 2012-05-10 | Протеоликс, Инк. | Пептидные эпоксикетоны для ингибирования протеасомы |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2008122779A (ru) | Соединения для ингибирования фермента | |
AU2009265362B2 (en) | Chemical compounds 251 | |
CA3014572C (en) | Acid addition salts of piperazine derivatives | |
CN102712624B (zh) | 吲哚化合物及其制药用途 | |
ES2650598T3 (es) | Inhibidores de la proteína humana tirosina fosfatasa y su uso | |
US7119104B2 (en) | Activator of peroxisome proliferator-activated receptor delta | |
CN101505752A (zh) | 脯氨酸羟化酶抑制剂 | |
RU2007126825A (ru) | Производные 2-арилпропиновой кислоты и фармацевтические композиции, их включающие | |
CA2522024A1 (en) | Cgrp receptor antagonists | |
SE449099B (sv) | 3,4-disubstituerade 1,2,5-tiadiazol-1-oxider och 1,1-dioxider, forfarande for deras framstellning samt farmaceutiska kompositioner innehallande dessa | |
DK200001556A (da) | Substituerede thiazolidindionderivater | |
HUP0302380A2 (hu) | Cisztein-proteázok reverzibilis inhibitoraiként alkalmazható új spiroheterociklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
WO2003037894A1 (en) | 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors | |
SK8202003A3 (en) | Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them | |
MXPA02007021A (es) | Derivados de 8,8a-dihidro-indeno[1,2-ditiazol sustituidos en la posicion 8a, metodo para su produccion y uso como medicamentos, por ejemplo como agentes anorecticos. | |
KR20080110393A (ko) | 항진균 활성을 갖는 트라이아졸 유도체, 이의 제조방법 및이를 함유하는 약학 조성물 | |
KR100340353B1 (ko) | 티아졸리딘디온의 개선된 제조방법 및 티아졸리딘디온 | |
KR880006196A (ko) | 알레르기 및 염증 치료제인 디하이드로피리딘 | |
JP2004067697A6 (ja) | 新規なチアゾリジンジオン及びその使用 | |
US5693651A (en) | Quinoline derivatives | |
Aldujaili et al. | Preparation and characterization of some new benzothiazole-heterocyclic derivatives | |
WO2008043733B1 (en) | 3- (benzo [d] [1,3] dioxol-5-ylmethyl) -4- (thio) oxo-2- (thio) oxo-azolidin-5-ylidene derivatives as antibacterial agents | |
CA1268759A (en) | Copper-mediated oximation reaction | |
AU2006212209B2 (en) | [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-S-transferase and NADPH quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular | |
WO1998054163A1 (fr) | Derives de 1,2,3-thiadiazole, agent regulant les maladies des vegetaux et procede d'utilisation de ces derives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20140312 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20191110 |